Search filters

Filters
Clear All

Phase

  • 67
  • 68
  • 1
  • 82
  • 60
  • 13
  • 192
  • 559
  • 217
  • 9
  • 22
  • 531
  • 559
  • 3

Found 562 Barrett's Esophagus trials

A listing of Barrett's Esophagus medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

99 years or below
All genders
This clinical study will consist of a post-market evaluation of the accuracy and user satisfaction of the System in a high volume single academic site. The study will compare overall anesthesia provider satisfaction with the System and the current approach for delivering and charting IV bolus medications. A small cohort …
99 years or below
All genders
Interventional
The purpose of this study is to compare the effectiveness and implementation of two suicide prevention strategies for autistic youth: the Safety Planning Intervention tailored for Autistic individuals (SPI-A) and SPI-A plus follow-up care (SPI-A+). Participants are 150 clinicians and 1500 autistic youth (ages 15-24) who receive either SPI-A or …
99 years or below
All genders
Phase 4
This is a prospective, multi-center, double-blind, randomized, placebo-controlled, parallel-group, exploratory Phase 4 study. The purpose is to identify the effect of selexipag on daily life physical activity assessed by a wearable device in patients with PAH (WHO Group 1). Approximately 100 patients will be enrolled in the study at 45 …
 Study comparing the effect of crizanlizumab plus standard of care to standard of care alone on renal function in sickle cell disease patients,with chronic kidney disease due to sickle cell nephropathy (STEADFAST).
16 years - 99 years
All genders
Phase 2
The main purpose of the study is to explore the effect of crizanlizumab on kidney function in people with long-term kidney disease caused by SCD. Kidney function of patients who receive crizanlizumab in addition to any regularly prescribed medications will be compared to that of patients who receive their regularly …
 FES PET/CT in Endocrine Refractory Breast Cancer
18 years - 99 years
All genders
Patients with recurrent or metastatic ER+ breast cancer, who have failed prior endocrine therapy may be eligible for this study.  Patients may participate in this study, if they are at least 18 years of age, most participants will be receiving care at the clinical practices of the University of Pennsylvania. …
 Multicenter  randomized  double-blind  parallel-group  add-on  superiority study to compare the efficacy and safety of ponesimod to placebo in subjects with active relapsing multiple sclerosis who are treated with dimethyl fumarate (Tecfidera )
99 years or below
All genders
Phase 3
This is a study to find out whether patients with active forms of Relapsing Multiple Sclerosis (RMS) who are treated with dimethyl fumarate (Tecfidera®) can be treated better by the addition of ponesimod (study drug). The purpose is also to evaluate the effect on disability and the safety of these …
99 years or below
All genders
The HeartMate 3 requires medicines to keep your blood from clotting knowing as “blood thinners” which can both be anticoagulants and antiplatelet drugs. The standard drugs given when you have the HeartMate 3 are warfarin and aspirin. This study is investigating whether the combination of these drugs as compared to …
 Innovative Combination Immunotherapy for Metastatic Triple Negative Breast Cancer (TNBC)
18 years - 99 years
Female
Phase 2
This phase II trial studies how well avelumab in combination with binimetinib, utomilumab, or anti-OX40 antibody PF-04518600 works in treating patients with triple negative breast cancer that is stage IV or is not able to be removed by surgery (unresectable) and has come back (recurrent). Immunotherapy with checkpoint inhibitors like …
18 years - 75 years
All genders
Phase 2
Interventional
The purpose of this study is to determine the safety and tolerability of an experimental medication PLN-74809 to treat primary Sclerosing Cholangitis (PSC), a rare, long-term liver disease affecting the bile ducts (small tubes) inside and outside the liver. Participants will visit the study center 8 times within 22 weeks. …
18 years - 65 years
All genders
Phase 3
Interventional
The Study Product we are testing in this research study is called STx-02. This study is being done to learn more about how safe, tolerable and effective the Study Product is in participants with T1D with impaired awareness of low blood sugar and who have severe hypoglycemia. Participation could last …
391 - 400 of 562